TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07720271: Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9)

Sponsor: Novo Nordisk A/S · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 950 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,267,416

Rescue Site Savings

+$7,448,752

Unlock Full NCT07720271 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07720271 Rescue Dossier →